HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Noyes, K. Articles by Holloway, R. G. Search for Related Content PubMed PubMed Citation Articles by Noyes, K. Articles by Holloway, R. G. Related Collections Parkinson's disease/Parkinsonism All epidemiology Risk factors in epidemiology

What is the risk of developing parkinsonism following neuroleptic use?

From the Department of Community and Preventive Medicine (K.N., H.L., R.G.H.) and the Department of Neurology (R.G.H.), University of Rochester School of Medicine, Rochester, NY.

Address correspondence and reprint requests to Dr. Katia Noyes, Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Avenue, Box 644, Rochester, NY 14620; e-mail: katia_noyes{at}urmc.rochester.edu

Use of neuroleptic medications is common among elderly patients. Using multivariate models, the authors found that use of antipsychotic medications, age, and disability were strong predictors of developing self-reported Parkinson disease (PD) in the subsequent year among 1992 to 2000 Medicare Current Beneficiary Survey participants. Although more research is needed, these data suggest that 126 Medicare beneficiaries would need to be treated with neuroleptic medications to cause one additional case of self-reported PD.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down to the Table of Contents for the March 28 issue to find the title link for this article.

The analyses and research efforts were supported by research grants K01 AG 20980 from the National Institute of Aging (K.N., H.L.) and K24 NS4 2098 from the National Institute of Neurological Disorders and Stroke (R.G.H.). The use of the Medicare Current Beneficiary Survey was covered by the Data Use Agreement #12874.

Disclosure: The authors report no conflicts interest.

The preliminary results of this study were presented at the International Society for Pharmacoeconomics and Outcomes Research 10th Annual Research Meeting in Washington, DC, May 16, 2005. The study was approved by the University of Rochester Research Subject Review Board.

Received September 12, 2005. Accepted in final form December 6, 2005.

This article has been cited by other articles:

				C. Kenney, C. Hunter, A. Davidson, and J. Jankovic Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia J. Clin. Pharmacol., March 1, 2008; 48(3): 379 - 384. [Full Text] [PDF]